Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aveo Pharmaceuticals (NQ: AVEO )

6.820 USD -0.190 (-2.71%)
Official Closing Price Updated: 7:39 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 838,900
Open 6.950
Bid (Size) 6.830 (1)
Ask (Size) 6.970 (1)
Prev. Close 7.010
Today's Range 6.750 - 6.980
52wk Range 3.600 - 18.24
Shares Outstanding 118,867,471
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines
AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen... 
From Business Wire News Releases
AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the... 
From Business Wire News Releases

Performance

YTD
+14.24%
+14.24%
1 Month
-55.37%
-55.37%
3 Month
-9.19%
-9.19%
6 Month
+4.28%
+4.28%
1 Year
+81.87%
+81.87%

More News

Read More
AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock
From Business Wire News Releases
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Tags News SLGL REGN
From Benzinga
AVEO Announces Proposed Public Offering of Common Stock
From Business Wire News Releases
AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance
From Business Wire News Releases
Thinking about buying stock in Super League Gaming, Welbilt, Oramed Pharmaceuticals, AVEO Pharmaceuticals, or Oncolytics Biotech?
From PR Newswire
AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update
From Business Wire News Releases
How The Parts Add Up: IWO Targets $355
Tags ETFs
From ETF Channel
AVEO Oncology to Regain Ex-North American Rights to AV-203
From Business Wire News Releases
AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Car
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.